Dongyang Guangyao (06887.HK) independently developed a new nucleic acid drug for hepatitis B that has been approved for clinical use in China.

According to the China Fortune Financial APP, the National Medical Products Administration's Drug Evaluation Center publicly announced that HECN30227, an siRNA therapy developed independently by Eastern Sunshine Pharmaceutical (06887.HK), has obtained implied approval for clinical trials and has been approved to conduct clinical trials for the indication of chronic hepatitis B (hereinafter referred to as hepatitis B). Currently, there are no approved siRNA drugs for hepatitis B worldwide.